An individual M&A theme focused on expanding the central nervous system business through the acquisition of Avanir Pharmaceuticals, incorporating its psychiatric and neurological product portfolio and business platform. It also includes organizational integration through the absorption-type merger into Otsuka America Pharmaceutical after the acquisition.